As a result of the current Federal government funding situation, the information on this website may not be up to date or acted upon.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit

Updates regarding government operating status and resumption of normal operations can be found at

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeTrial IDs
Phase IBiomarker/Laboratory analysis, TreatmentActive18 and overA8081001
NCI-2009-01775, PROFILE 1001, NCT00585195

Trial Description


PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor

cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor

tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma

kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is

the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.

Eligibility Criteria

Inclusion Criteria:

Advanced malignancies (except leukemias), histologically proven at diagnosis;

Histologically confirmed advanced malignancies that are known to be sensitive to

PF-03241066 inhibition, e.g. ALK, c-MET and ROS

Solid tumors must have measurable disease (Recommended Phase 2 Dose Cohort patients

with non-measurable disease may enter on a case-by-case basis); not required for DDI


Adequate blood cell counts, kidney function, liver function and Eastern Cooperative

Oncology Group (ECOG) score of 0 or 1 (for the Recommended Phase 2 Cohort, a ECOG

score of 2 may be allowed on a case-by-case basis)

Exclusion Criteria:

Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of

starting study treatment, depending on the patient cohort

Prior stem cell transplant except of patients with neuroblastoma, lymphoma or myeloma

Active or unstable cardiac disease or heart attack within 3 months of starting study


Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators


    Trial Sites



    UC Irvine Health/Chao Family Comprehensive Cancer Center

    Sai-Hong Ignatius Ou
    Principal Investigator


    University of Colorado Cancer Center - Anschutz Cancer Pavilion

    Ross Camidge
    Principal Investigator


    University of Chicago Comprehensive Cancer Center

    Ravi Salgia
    Principal Investigator


    Beth Israel Deaconess Medical Center

    Daniel C Cho
    Principal Investigator

    Brigham and Women's Hospital

    Geoffrey Ira Shapiro
    Principal Investigator

    Dana-Farber Cancer Institute

    Geoffrey Ira Shapiro
    Principal Investigator


    Massachusetts General Hospital

    Jeffrey W. Clark
    Principal Investigator


    Wayne State University/Karmanos Cancer Institute

    Ulka N. Vaishampayan
    Principal Investigator

    North Carolina
    Chapel Hill

    UNC Lineberger Comprehensive Cancer Center

    Jared Weiss
    Principal Investigator


    Ohio State University Comprehensive Cancer Center

    Gregory A. Otterson
    Principal Investigator


    University of Pittsburgh Cancer Institute (UPCI)

    Mark Anthony Socinski
    Principal Investigator

    Link to the current record.
    NLM Identifier NCT00585195

    Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the record via the link above for more information about participating sites.